Searchable abstracts of presentations at key conferences in endocrinology

ea0095oc1.2 | Oral Communications 1 | BSPED2023

45,X/46,XY DSD with gender dysphoria: the conundrum around pubertal induction

Chatterjee Sumana , Alderson Julie , Edwards Zoe , Mcandrew Fiona , Williams Cara , Das Urmi , Awad Karim , Park Julie , Giri Dinesh

Introduction: Mixed gonadal dysgenesis (MGD) is a rare form of difference in sex development (DSD) characterised by mosaic karyotype of 45,X/46,XY and dysgenetic gonads. Gender dysphoria can be associated, the frequency of which is unknown. We describe 2 cases of MGD with gender dysphoria and the conundrum around pubertal induction.Case 1: An 8-year-old, reared as a girl, presented with longstanding concerns about appear...

ea0012s3biog | Society for Endocrinology Medal Lecture | SFE2006

Society for Endocrinology Medal Lecture

Costagliola S

VKK Chatterjee, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom AbstractKrishna Chatterjee graduated from Cambridge and completed his clinical training in Oxford. He first trained in endocrinology at Hammersmith Hospital, London and subsequently undertook research in the Thyroid Unit at Massachusetts General Hospital, Boston. In 1990, he returned to Cambridge as a Wellcome Senior Clinical Res...

ea0051oc2.1 | Oral Communications 2 | BSPED2017

Discordant TSH measurements in an euthyroid child due to a homozygous TSHbeta subunit gene variant with variable immunoreactivity

van Walree Eva , Hendriks A Emile J , Moran Carla , Nicholas Adeline K , Lyons Greta , McGowan Anne , Halsall David , Oddy Sue , Chatterjee V Krishna , Schoenmakers Nadia

Introduction: Thyroid function tests are frequently undertaken in children with non-specific symptoms suggestive of thyroid dysfunction. Infrequently, susceptibility of automated thyroid hormone assays to interference may generate misleading results, with the potential for inappropriate diagnosis and management. We report an unusual case with apparent subclinical hyperthyroidism, due to negative interference in particular TSH assay platforms, with an underlying genetic basis.<...

ea0051oc5.6 | Oral Communications 5 | BSPED2017

Phenotypic spectrum and response to recombinant human IGF1(rhIGF1) therapy in patients with homozygous intronic pseudoexon ()GH receptor mutations

Chatterjee Sumana , Rose Stephen , Mushtaq Talat , Clayton Peter , Ten Svetlana , Bhangoo Amrit , Kumbattae Uma , Dias Renuka , Shapiro Lucy , Metherell Louise , Savage Martin , Storr Helen

Objectives: Patients with homozygous 6Ψ mutations have GH insensitivity (GHI). We previously described spectrum of clinical and biochemical phenotypes of 11 6Ψ patients (David et al. JCEM 2007;92:655) and now report 9 additional patients. Response to rhIGF-I therapy has not previously been assessed.Methods: 20 6Ψ patients (12 M, 11 families, mean age 4.0±2.2 year) were diagnosed genetically in our centre. Continuous ...

ea0084ps2-09-84 | Thyroid Hormone ACTION | ETA2022

Molecular mechanisms underlying action of triac in resistance to thyroid hormone BETA (RTHβ)

Liao Wenjun , van Geest Ferdy , Marelli Federica , Campi Irene , Moran Carla , Lyons Greta , Agostini Maura , Peeters Robin , Chatterjee Krishna , Persani Luca , Meima Marcel , Edward Visser W.

Background: Resistance to thyroid hormone (TH) beta (RTHβ), caused by mutations in THRB, is characterized by elevated serum (F)T4 accompanied by non-suppressed TSH concentrations. Disease features arise from variable resistance to TH action in tissues expressing Thyroid Hormone Receptor (TR) β (hypothalamus, pituitary, liver) and from thyrotoxic effects in tissues expressing TRα (heart, bone, brain). In symptomatic patients, treatment mainly involves be...

ea0086oc3.1 | Reproductive and Neuroendocrinology | SFEBES2022

Depot somatostatin receptor ligand therapy reverses tissue thyrotoxicosis in thyrotropinomas and aids microadenoma localization via 11C-Methionine PET

Koulouri Olympia , MacFarlane James , Bashari Waiel , Gillett Daniel , Senanayake Russell , Halsall David , Oddy Sue , Powlson Andrew , Serban Laura , Moran Carla , Schoenmakers Nadia , Chatterjee Krishna , Gurnell Mark

Context: Surgery is the first-line treatment option for thyrotropinomas, but medical therapy with somatostatin receptor ligands (SRL) may be used as neoadjuvant treatment and to facilitate safe surgery.Objectives: To determine the extent to which neoadjuvant SRL (i) corrects clinical, laboratory and tissue hyperthyroidism in thyrotropinomas, (ii) induces tumour shrinkage in macroadenomas, and (iii) aids microadenoma detection by 11C-methionine...

ea0065p402 | Thyroid | SFEBES2019

Rates of maternal complications from TRAb positive pregnancies are low, but strongly positive TRAb in later pregnancy is associated with adverse neonatal outcomes

Doran Isabel Huang , McFarlane James , Glasgow John Clark , Bikou Eirini , Inetinbor Emilomon , Lia Charleen , Stears Anna , Wood Diana , Gajewska-Knapik Katarzyna , Ogilvy-Stuart Amanda , Chatterjee Krishna , Moran Carla

Introduction: Graves’ disease during pregnancy may cause maternal or neonatal complications, including arrhythmia, thyroid storm, congenital anomalies and neonatal thyroid dysfunction (TD). The optimal timing and frequency of TRAb measurement in pregnant women with a history of TD, and whether fetal monitoring could be limited to those with a strongly positive TRAb, is unclear.Methods: Retrospective case note review of women with elevated TRAb (>1 i...

ea0066oc4.7 | Oral Communications 4 | BSPED2019

Novel variants in the Leucine-zipper-like transcription regulator 1 (LZTR1) gene cause Noonan syndrome phenotype by upregulation of the RAS-MAPKinase pathway

Chatterjee Sumana , Bertola Debora , Agwu Chizo , Karantza Maria , Cottrell Emily , Shapiro Lucy , Maharaj Avinaash V , Williams Jack , Savage Martin O , Gaston-Massuet Carles , Metherell Louise A , Storr Helen L

Objectives: Noonan Syndrome (NS) is an autosomal dominant multi-system disorder characterised by short stature (SS), distinctive facial features and cardiovascular abnormalities. Mutations in multiple genes regulating the RAS-MAPK pathway have been identified in NS including 5 recently described novel LZTR1 variants. We identified 2 novel LZTR1 variants in patients with features of growth hormone insensitivity and NS. The molecular function of LZTR1 ...

ea0066p73 | Pituitary | BSPED2019

Three novel Growth Hormone Receptor (GHR) splicing mutations causing a spectrum of Growth Hormone Insensitivity

Cottrell Emily , Maharaj Avinaash , Ladha Tasneem , Chatterjee Sumana , Grandone Anna , Cirillo Grazia , del Giudice Emanuele Miraglia , Kostalova Ludmila , Vitariusova Eva , Hwa Vivian , Metherell Louise A , Storr Helen L

Introduction: Growth Hormone Insensitivity (GHI) is characterised by a triad of short stature (SS), IGF-1 deficiency and normal/high GH levels. ‘Classical’ GHI due to homozygous exonic GHR mutations results in extreme SS with dysmorphic and metabolic abnormalities. Heterozygous exon 9 GHR mutations are rare and exert dominant negative effects due to impairment of GHR dimerization/downstream signalling associated with a milder GHI phenotype. Only sev...

ea0049gp27 | Adrenal 3 | ECE2017

The role of in vivo metabolomics using H-MRS in SDH deficient disease

Casey Ruth , McLean Mary , Bassetti Madhu , Challis Ben , Simpson Helen , Gurnell Mark , Bulusu Ramesh , Marker Alison , Giger Olivier , Allinson Kieran , Chatterjee Krishna , Maher Eamonn , Gallagher Ferdia

Tumours caused by mutations in the SDH enzyme complex have a unique tumour metabolome due to a truncated citric acid cycle. The accumulation of the onco-metabolite succinate is believed to drive tumourigenesis. The aim was to investigate the role of MRI spectroscopy (H-MRS) to detect in vivo succinate elevations in suspected SDH deficient tumours including GIST, phaeochromocytoma/paraganglioma (PPGL) and pituitary adenomas (PA). Suitable patients were identified based...